Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAZD 4547 is a potent and selective FGFR1, FGFR3 and FGFR2 tyrosine kinase inhibitor (IC50 values are 0.2 1.8, and 2.5 nM, respectively). It shows selectivity for FGFR across a range of unrelated tyrosine and serine/threonine kinases, including IGFR (>2,900-fold), CDK2 (>50,000-fold), and p38 (>50,000-fold). In vitro, it has antiproliferative effects on tumor cell lines with deregulated FGFR expression. In vivo, AZD 4547 exhibits dose-dependent inhibition of tumor growth in an FGFR-driven human tumor xenograft mice model. It suppresses osteoclastogenesis and tumor-induced osteolysis in an orthotopic breast cancer bone metastasis mouse model. AZD 4547 is orally bioavailable.
M. Wt | 463.56 |
Formula | C26H33N5O3 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 1035270-39-3 |
PubChem ID | 51039095 |
InChI Key | VRQMAABPASPXMW-HDICACEKSA-N |
Smiles | C[C@H]1CN(C2=CC=C(C=C2)C(NC3=NNC(CCC4=CC(OC)=CC(OC)=C4)=C3)=O)C[C@H](N1)C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 9.27 | 20 |
The following data is based on the product molecular weight 463.56. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 10.79 mL | 53.93 mL | 107.86 mL |
1 mM | 2.16 mL | 10.79 mL | 21.57 mL |
2 mM | 1.08 mL | 5.39 mL | 10.79 mL |
10 mM | 0.22 mL | 1.08 mL | 2.16 mL |
References are publications that support the biological activity of the product.
Gavine et al (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72 2045 PMID: 22369928
Kang et al (2019) A selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Sci.Rep. 9 8726 PMID: 31217507
If you know of a relevant reference for AZD 4547, please let us know.
Keywords: AZD 4547, AZD 4547 supplier, AZD4547, potent, selective, tyrosine, kinases, inhibitors, inhibits, FGFR, orally, bioavailable, osteolysis, cancer, osteoclastogenesis, 7823, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for AZD 4547. Do you know of a great paper that uses AZD 4547 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review AZD 4547 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.